Q-omics provides the consensus-scored ATXN7L2 profile across patient tissues and cancer cell-line models. ATXN7L2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ATXN7L2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ATXN7L2 RNA expression shows 19,159 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where ATXN7L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATXN7L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATXN7L2 survival associations across molecular data types. ATXN7L2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATXN7L2 RNA expression–survival associations across cancer types. High ATXN7L2 expression shows unfavorable associations in KIRC, ACC, LIHC, SKCM and UCEC, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ATXN7L2 RNA expression.
This table summarizes ATXN7L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ATXN7L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATXN7L2 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, STAD, BLCA and LUSC. The COAD box plot shows higher ATXN7L2 RNA expression in tumor versus normal tissue (log2 FC = +0.935, t-test p < 0.001).
This table shows molecular features associated with ATXN7L2 in patient tissues and cancer cell lines. In patient samples, ATXN7L2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATXN7L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
